drugset
drugset / Trial / NCT00544674

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

NCT00544674 ↗

Phase 2 Terminated 5 enrolled Proacta, Incorporated
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well PR-104 works in treating patients with previously untreated or relapsed small cell lung cancer (SCLC).

Timeline

Start
2007-08
Primary completion
2008-07
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject PR104 Small molecule 1100 mg/m2 Intravenous

Indications

lung cancer